Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUTEP LIMITED Director's Dealing 2014

Nov 27, 2014

65122_rns_2014-11-27_d81b6501-41f4-4064-b92b-187d961d62b9.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: PRIMA BIOMED LIMITED (ASX:PRR) ACN:[90 009 237 889 ]

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Mr Pete Meyers Date of Last Notice: 13 February 2014

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
N/A
Date of change 28 November 2014
No. of securities held prior to change N/A
Class 1) Ordinary Fully Paid shares
2) Performance Rights
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number acquired 1) Ordinary Fully Paid Shares 1) Ordinary Fully Paid Shares 1) Ordinary Fully Paid Shares
Shares Options
Direct 1,715,686 -
Indirect - -
Total 1,715,686 -
2) 7,720,588
Number disposed 1,715,686 Performance Rights
Value/Consideration
Note: If consideration is non-cash, provide details and
estimated valuation
Nil
The
Performance
Rights
are
issued
as
remuneration for services as a director as Mr
Meyers
is
taking
his
fees
entirely
in
Performance Rights in lieu of cash and in
accordance
with
shareholder’s
approval
obtained at Annual General Meeting on 14th
November 2014.
No amount is payable upon exercise of the
Performance Rights for shares after vesting.
No. of securities held after change 1) Ordinary Fully Paid Shares
Shares
Options
Direct
1,715,686
-
Indirect
-
-
Total
1,715,686
-
2) 6,004,902 Performance Rights
  • See chapter 19 for defined terms. Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Nature of change
Example: on-market trade, off-market trade, exercise of
options, issue of securities under dividend reinvestment
plan, participation in buy-back
1) 7,720,588 Performance Rights were issued in
accordance
with
shareholder’s
approval
obtained at Annual General Meeting on 14th
November 2014. The first tranche of 1,715,686
vested immediately upon approval, for director
services already performed. After vesting of
the first tranche, 6,004,902 Performance
Rights remain to be vested subject to Mr
Meyers meeting his service conditions over 3
subsequent annual tranches.
2) Acquiring 1,715,686 shares upon exercise of
first tranche of performance rights. One
ordinary fully paid share was acquired for each
Performance Right that vested.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded No during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided on what date was this provided?

28.11.2014

  • See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002